Coverage Guide · Updated April 28, 2026
Does UnitedHealthcare Cover Wegovy? (2026 Coverage Guide)
Often covered with prior auth for UnitedHealthcare members in 2026. Wegovy is FDA-approved for chronic weight management. Coverage depends on your specific plan, employer benefits, and prior authorization rules.
1. UnitedHealthcare coverage status for Wegovy
| Detail | Status |
|---|---|
| Plan type | Commercial |
| Coverage status | Often covered with prior auth |
| FDA indication | chronic weight management |
| List price | $1349/mo (cash-pay retail) |
| Manufacturer direct | NovoCare cash-pay, about $499/mo |
| Appeal success rate | ~38% when denied |
2. UnitedHealthcare's coverage rules
UHC commercial plans typically cover GLP-1s for the FDA indication with prior authorization. Step therapy through cheaper drugs is sometimes required. UHC Medicare Advantage does not cover for weight loss.
3. Prior authorization requirements
Most UnitedHealthcare plans require:
- BMI 30+ (or 27+ with at least one comorbidity such as type 2 diabetes, hypertension, sleep apnea, or non-alcoholic fatty liver disease)
- Documented prior weight-loss attempts (often 6 months of supervised diet and exercise)
- No contraindications (medullary thyroid carcinoma history, MEN-2)
- Some plans require step therapy through a cheaper drug first (often phentermine or metformin)
Prior auth approval typically takes 3 to 14 days. Some prescribers offer PA submission as part of the visit, which speeds the process.
4. If denied: how to appeal
UnitedHealthcare appeals succeed about 38% of the time when prepared properly. Steps:
- Request the formal denial letter (your right under federal law). It will list the specific reason for denial.
- Have your prescriber write a letter of medical necessity. Should document BMI, comorbidities, prior weight-loss attempts, contraindications to cheaper alternatives, and any cardiovascular risk factors.
- Submit the appeal within the deadline (usually 30 to 180 days depending on plan).
- If denied at first appeal, escalate to second-level review or external review.
5. If uncovered: cheapest alternatives for UnitedHealthcare members
- NovoCare cash-pay: about $499/mo. Direct from the manufacturer, no insurance required.
- Manufacturer savings card: as low as $25/mo for eligible commercial-insurance patients. May apply to your plan.
- Compounded semaglutide: $80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide. Cash-pay only.
- Switch to the diabetes-indicated version (Mounjaro or Ozempic) if you have type 2 diabetes, which has higher coverage rates.
FAQ
Does UnitedHealthcare cover Wegovy in 2026?
Often covered with prior auth for UnitedHealthcare members. Wegovy is FDA-approved for chronic weight management. Coverage depends on your specific plan, employer benefits (for commercial plans), and prior authorization requirements. UHC commercial plans typically cover GLP-1s for the FDA indication with prior authorization. Step therapy through cheaper drugs is sometimes required. UHC Medicare Advantage does not cover for weight loss.
What is the prior authorization process for Wegovy on UnitedHealthcare?
Most UnitedHealthcare plans require: BMI 30+ (or 27+ with comorbidity), documented prior weight-loss attempts (often 6 months), no contraindications, and sometimes step therapy through cheaper drugs first. Approval usually takes 3 to 14 days.
If UnitedHealthcare denies Wegovy, can I appeal?
Yes. UnitedHealthcare appeal success rate for GLP-1 denials is approximately 38%. Strongest appeals document BMI, comorbidities (diabetes, hypertension, sleep apnea, NAFLD), prior weight-loss attempts, and any contraindications to alternative drugs.
If insurance won't cover Wegovy, what is the cheapest alternative?
Three options. First, NovoCare cash-pay from the manufacturer at about $499/mo. Second, the manufacturer savings card if you have commercial insurance ($25/mo for eligible patients). Third, compounded semaglutide from a licensed compounding pharmacy ($80 to $349/mo for compounded semaglutide, $132 to $600/mo for compounded tirzepatide).